Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference
Ceribell Announces FedRAMP High Authorization, Expanding Approval For Its AI-Powered Point-Of-Care EEG Across Federal Healthcare Systems
Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
TD Cowen Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $36
Ceribell, Inc.: Promising Growth Trajectory and Strong Market Potential Reinforce Buy Rating
CeriBell Says FDA Clears Electrographic Seizure Detection Algorithm
Express News | FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older
BofA Securities Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $32
CCORF Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $33
William Blair Maintains Ceribell(CBLL.US) With Buy Rating
Top Midday Gainers
Sector Update: Health Care Stocks Gain in Afternoon Trading
Sector Update: Health Care
CeriBell Shares Jump After Claiming Inventory in US Provides Buffer From Tariffs Until Q4
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Does CeriBell (NASDAQ:CBLL) Have A Healthy Balance Sheet?
U.S. Tariffs Prompt Ceribell To Estimate Limited Near-Term Impact On Costs For China-Sourced Headbands, With Sufficient U.S. Inventory To Cover Demand Through Q3 2025 And No Material Financial Effect Expected Until Q4
Express News | Ceribell Inc - No Material Impact to Financial Results From Incremental Tariffs Until at Least the Fourth Quarter of 2025
Express News | Ceribell Inc - Expects 8-10 Percentage Point Impact on Gross Margins Due to Tariffs - SEC Filing
Express News | Ceribell Inc - Expects Sufficient Supply of Headband Product Through Q3 2025 - SEC Filing